Literature DB >> 12613659

Orexins and their receptors: structural aspects and role in peripheral tissues.

T Voisin1, P Rouet-Benzineb, N Reuter, M Laburthe.   

Abstract

Orexins, also named hypocretins, were discovered in 1998 by subtractive cDNA cloning or orphan receptor technologies. Prepro-orexin is enzymatically matured into two peptides, orexin-A and orexin-B which are 33- and 28-amino-acid peptides, respectively. Two cloned orexin receptors OX1R and OX2R are serpentine G-protein-coupled receptors, both of which bind orexins and are coupled to Ca2+ mobilization. Orexins are neuropeptides present in hypothalamic neurons that project throughout the central nervous system to nuclei involved in the control of feeding, sleep-wakefulness, neuroendocrine homeostasis and autonomic regulation. The interest of investigators in orexins has focused on narcolepsy, since genetic or experimental alterations of the orexin system are associated with this sleep disorder. However, orexins are not restricted to the hypothalamus and together with their receptors they are expressed in peripheral tissues. This new multifaceted aspect of orexin biology is reviewed here in descriptions of (i) the proform, maturation and structure of orexins, (ii) the structure, signal transduction and pharmacology of orexin receptors and (iii) the expression of orexins and orexin receptors as well as their biological role in the hypothalamus-pituitary-adrenal axis, gastrointestinal tract, endocrine pancreas and other peripheral tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12613659     DOI: 10.1007/s000180300005

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  27 in total

1.  Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

2.  Functional characterization of an allatotropin receptor expressed in the corpora allata of mosquitoes.

Authors:  Marcela Nouzova; Anne Brockhoff; Jaime G Mayoral; Marianne Goodwin; Wolfgang Meyerhof; Fernando G Noriega
Journal:  Peptides       Date:  2011-08-03       Impact factor: 3.750

Review 3.  Orexin: pathways to obesity resistance?

Authors:  Tammy A Butterick; Charles J Billington; Catherine M Kotz; Joshua P Nixon
Journal:  Rev Endocr Metab Disord       Date:  2013-12       Impact factor: 6.514

Review 4.  The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs.

Authors:  Marc Laburthe; Thierry Voisin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 5.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

6.  Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.

Authors:  P Malherbe; E Borroni; L Gobbi; H Knust; M Nettekoven; E Pinard; O Roche; M Rogers-Evans; J G Wettstein; J-L Moreau
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

7.  Orexins control intestinal glucose transport by distinct neuronal, endocrine, and direct epithelial pathways.

Authors:  Robert Ducroc; Thierry Voisin; Aadil El Firar; Marc Laburthe
Journal:  Diabetes       Date:  2007-07-12       Impact factor: 9.461

8.  Orexins/hypocretins acting at Gi protein-coupled OX 2 receptors inhibit cyclic AMP synthesis in the primary neuronal cultures.

Authors:  Anna Urbańska; Paulina Sokołowska; Agata Woldan-Tambor; Kaja Biegańska; Britta Brix; Olaf Jöhren; Magdalena Namiecińska; Jolanta Barbara Zawilska
Journal:  J Mol Neurosci       Date:  2011-05-06       Impact factor: 3.444

9.  Orexin-1 receptor co-localizes with pancreatic hormones in islet cells and modulates the outcome of streptozotocin-induced diabetes mellitus.

Authors:  Ernest Adeghate; Maria Fernandez-Cabezudo; Rashed Hameed; Hussain El-Hasasna; Mohamed El Wasila; Tariq Abbas; Basel Al-Ramadi
Journal:  PLoS One       Date:  2010-01-06       Impact factor: 3.240

10.  Orexin A suppresses the growth of rat C6 glioma cells via a caspase-dependent mechanism.

Authors:  Kaja Biegańska; Paulina Sokołowska; Olaf Jöhren; Jolanta B Zawilska
Journal:  J Mol Neurosci       Date:  2012-05-17       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.